Q2 2025 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) reported a 10% year-over-year revenue growth, reaching $181 million in Q2 2025.
- The clinical business showed strong performance with a 16% increase in revenue and a 13% organic growth rate.
- NGS testing accounted for 32% of total clinical revenue, growing by 23% over the prior year.
- The company successfully renegotiated several managed care agreements, expected to positively impact revenue in the second half of 2025.
- NeoGenomics Inc (NEO) launched the PanTracer Liquid Biopsy, expected to enhance NGS growth and positively impact patient care.
- Non-clinical revenue declined by 26% year-over-year, driven by weakness in pharma and biotech customer demand.
- The company missed its Q2 revenue guidance, attributing the shortfall to macroeconomic conditions affecting the pharma sector.
- NeoGenomics Inc (NEO) revised its 2025 financial guidance downward due to lower than expected pharma revenue and delayed product launches.
- The delay in the PanTracer Liquid Biopsy launch resulted in lower revenue and a lower than targeted NGS growth rate.
- The company faces challenges in the pharma services line due to market uncertainty, including NIH funding, drug pricing, and clinical trial enrollment issues.
Good morning and welcome to the NeoGenomics second quarter 2025 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded.
I will now turn the call over to Kendra Webster, Vice President of Investor Relations.
Thank you, Tom, and good morning everyone. Welcome to the NeoGenomics second quarter 2025 financial results call. With me today to discuss the results are Tony Zook, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team will be available for the Q&A portion of our call.
This call is being simultaneously webcast, and we will be referring to the slide presentation that has been posted to the investors tab on our website at ir.neogenomics.com. During this call, we will make forward-looking statements regarding our future performance, business strategy, and financial guidance. We caution you that the actual events or results could differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
